• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

FDA starts speedy review of Enhertu in lung cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 19, 2022 at 11:12: AM
via AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its current uses in breast and gastric cancer.

article source
 




Top Bottom
Back
Quote